Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Upfront Chemotherapy With Trastuzumab in Patients With HER2-Positive Breast Cancer
- Vinorelbine With Pertuzumab and Trastuzumab as First Line in HER2+ Metastatic Breast Cancer
- New Combination Options for HR+ Patients: An Update from SABCS 2016
- Fulvestrant 500 mg Versus Anastrozole 1 mg for Hormone Receptor–Positive Advanced Breast Cancer
- ESMO 2016: Recap of Metastatic Breast Cancer
- Methylation Predicts Outcome in Metastatic Breast Cancer
- Positive Outcomes With Palbociclib and Letrozole
- Patients With Polymorphisms FCGR2A and FCGR3A Benefit From Adjuvant Trastuzumab for ERBB2/HER2–Positive Breast Cancer
- Managing Metastatic Breast Cancer: An Interview With Lee Schwartzberg, Reshma Mahtani, and Lillie Shockney—Part 5
- Epithelial to Mesenchymal Transition Drives Circulating Tumor Cell Heterogeneity